Investors

Corporate Governance

The law, our Articles of Association, internal codes and guidelines make up Mentis Cura's corporate governance framework and determines the duties and conduct of the various bodies within the company. Sound corporate governance practices support sustainable growth and builds trust between the Company's various stakeholders. We are committed to continously develop and strengthen our governance framework and aim to comply with industry best-practices for corporate governance.

Investor Calendar

Annual General Meeting Mentis Cura AS

20 May 2020

Extraordinary General Meeting Mentis Cura AS

16 April 2020

Extraordinary General Meeting Mentis Cura ehf

13 February 2020

Extraordinary General Meeting Mentis Cura AS

5 February 2020

Annual General Meeting Mentis Cura ehf

27 May 2019

Annual General Meeting Mentis Cura AS

13 May 2019

Releases and Presentations

Leadership

The Board of Directors is the highest decision making body within Mentis Cura between shareholders' meetings.

The Board appoints the group CEO. Claire Button was appointed CEO in April 2020.

Claire, PhD in Immunopharmacology, has worked with life science and healthtech ventures in leadership, commercial and team-building roles for over a decade. She co-founded several healthtech ventures, including those in the research tools, remote diagnostic and data-driven fields. She has significant experience working with early stage, high-growth businesses and their investors; partnering with them from the seed-fund stage, on to series A, onwards through to exit and beyond.

Board of Directors

The Board of Directors is appointed on an annual basis at the Annual General Meeting, or extraordinary shareholders meetings as applicable. The current members of the Board were elected at an Extraordinary General Meeting on 16 April 2020.

Friðrik Friðriksson

Friðrik Friðriksson

Chairman of the Board

Friðrik is the CFO of the Icelandic New Business Venture Fund. He has a diverse background as an executive in IT, retail and media, as well as chairing and serving on the board of various companies, organizations and funds. He has extensive experience in the reorganization of companies, mergers and acquisitions as well as management consulting.

Friðrik has a Cand. Oecon. degree from the University of Iceland, a Masters of economics and an MBA from Virginia Tech.

Joanne Hackett

Joanne Hackett

Board Director

Joanne is an accomplished strategist, scientist and entrepreneur with an extensive clinical research background and robust business development record. She has extensive experience in turning academic and clinical research into medical and commercial returns, and has managed and executed a multitude of complex business transactions in pharma, biotech, academia and healthcare. Joanne has created two companies that were sold to large multinationals and worked for organisations such as Genomics England, Pfizer Neusentis, UCLPartners and Cambridge University Health Partners. 

Joanne's  educational background includes Mount Allison University, King's College London, John's Hopkins University and the Harvard Stem Cell Institute, which span her undergraduate degree to postdoctoral fellowships.

 

Audun Abelsnes

Audun Abelsnes

Board Director

Audun is the managing director of Techstars Energy Accelerator and an investor that has served on the board of various companies.

He is a former management consultant at PriceWaterhouseCoopers in Oslo and Washington D.C. and was a visiting lecturer at the University of Oslo and Norwegian School of Management within the fields of entrepreneurship and innovation.

Audun holds an M.Sc. in International Marketing and Strategy from the Norwegian School of Management (BI).

Paul Mussenden

Paul Mussenden

Board Advisor

Paul has 25 years’ experience in the healthcare industry. He was General Counsel, Head of Strategic Affairs & Company Secretary at BTG plc from 2000 until its takeover in 2019 by Boston Scientific for US$4.2 billion. Paul was a member of the BTG Executive Team and Managing Director of the intellectual property licensing business, as well as MD of one of BTG’s small innovative medical device business units. Paul has extensive experience of strategy development, corporate finance, mergers & acquisitions, product licensing and driving business growth.

Paul is a non-executive director at Cydar Ltd, a UK Artificial Intelligence and medical imaging company and non-executive deputy chairman at LifeArc Ltd, a large UK self-funded healthcare charity.

Paul has a BSc (Hons) in Biotechnology and a Ph.D in molecular biology.

Investor Relations

Do you have any questions?